Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult3. fázis

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

A legfontosabb adatok

Ki végzi
ScandiBio Therapeutics AB
Hol
Törökország12 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
336 fő, tervezett
Kezdés
2026. okt.
Várható befejezés
2027. febr.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Combined metabolic activators
  • Collagen and maltodextrin
A regiszteradat frissítve
2026. október 27.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with gout and high uric acid in the blood. They take CMA2 supplements or a placebo (dummy product) for 4 weeks.

Életkor
18 years or older.
Nem
Men and women.
A betegség stádiuma
Gout diagnosed by the 2015 ACR-EULAR criteria, with at least one gout attack in the last three years. No gout flare in the 14 days before the start.
Korábbi kezelés
People whose uric acid-lowering medicine dose changed in the month before cannot join. No dietary supplements or anti-microbial medicines in the 1 week before. Some medicines must be at a stable dose for at least 14 days.
Biomarker vagy leletérték
High uric acid in the blood (7 mg/dl).

A részvétel fő kizáró okai

  • Gout flare not fully settled within 14 days before the start.
  • Kidney disease with S-creatinine > 1.30 mg/dL (115 µmol/L) or eGFR <30 mL/min/1.73 m2.
  • Uncontrolled diabetes (HbA1c > 8.4% (68 mmol/mol)), stroke, or active cancer.
  • High uric acid caused by another disease, such as blood cancers or Down's syndrome.
  • Pregnant or breastfeeding women.

A regiszter feltételei, szó szerint

Mind a 40 feltétel megnézéseKevesebb

Ki vehet részt

  • Men and women ≥ 18 years of age
  • Individuals with elevated uric acid blood levels (7 mg/dl) and at least one episode of gout during the last three years
  • Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria
  • Able to give written informed consent for participation in the study by the patient and/or legal representatives

Ki nem vehet részt

  • Patients who have received uric acid-lowering therapy with a change in dose within 1 month prior to inclusion
  • Acute gout flare within 14 days prior to randomization (i.e., any gouty arthritis episode with pain or swelling that has not fully resolved ≤14 days before randomization). Definition of Resolved (for the eligibility assessment): absence of joint pain at rest and no visible swelling at the previously affected joint(s) for at least 48 hours, and no requirement for escalation of anti-inflammatory therapy within that period
  • Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion
  • Use of anti-microbial agents later than one (1) week prior to inclusion
  • Drug and/or alcohol abuse
  • Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study
  • Females of childbearing potential who:; Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:; total abstinence (if it is their preferred and usual lifestyle); an intrauterine device or intrauterine hormone-releasing system (IUS); a contraceptive implant; an oral contraceptive (Subject must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.); have a vasectomized partner with confirmed azoospermia. Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation; It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide; NOTE: Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and estradiol <200 pmol/L is confirmatory])
  • Male participants who:; Plan to conceive a child or donate sperm during the study treatment period and for at least 90 days after the last dose of investigational product, or; Are unwilling to use effective contraception during the study and for at least 90 days after the last dose of investigational product
  • Lesch-Nyhan syndrome 2) Phosphoribosylpyrophosphate synthetase superactivity 3) Congenital myogenic hyperuricemia 4) Hematopoietic neoplasms (acute leukemia, lymphoma malignant, myeloproliferative disorder, myelodysplastic syndrome, etc) 5) Solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer, etc) 6) Non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia) 7) Rhabdomyolysis 8) Hypothyroidism 9) Polycystic kidney 10) Lead poisoning/lead nephropathy 11) Down's syndrome 12) Familial juvenile gouty nephropathy 13) Hyperlactacidemia 14) Glycogen storage disease type 1 27. Participants who are on the following treatment are required to be on a stable dose and same mode of administration for at least 14 days prior to screening and to keep the stable during the study. Participants are not permitted to initiate these drugs within 14 days prior to screening and during the study
  • Drugs or containing compound preparations that potentially affect SUA level:
  • Antituberculous drugs (pyrazinamide, ethambutol hydrochloride)
  • Hyperlipidemia drugs (fenofibrate, atorvastatin, rosuvastatin, pitavastatin)
  • History of stroke
  • History of brain trauma < 14 days
  • History of phenylketonuria
  • Known allergy for substances used in the study
  • Known allergy for strawberry
  • Known active malignancy
  • Dietary and physical therapy for the underlying disease
  • Uncontrolled diabetes (HbA1c > 8.4%)
  • Chronic kidney disease with S-creatinine > 1.30 mg/dL
  • Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 in the Screening Phase
  • Antihypertensives (losartan potassium)
  • Sodium-dependent glucose transporter (SGLT) 2 inhibitors
  • Uncontrolled diagnosed depression
  • Severe swallowing problems
  • PEG-feeding
  • Chronic diarrhoea
  • Active bronchial asthma at the time of screening
  • Known active psoriasis
  • Participants considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment
  • Females who are breastfeeding or pregnant at screening (as documented by a positive beta human chorionic gonadotropin [β-hCG] test)
  • Currently has secondary hyperuricemia:
  • Immunosuppressants (mizoribine, cyclosporin, tacrolimus hydrate)
  • Diuretics (thiazide diuretics, loop diuretics)
  • Theophylline

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.

A vizsgálat 2 csoportja

  • Treatment ArmA vizsgált kezelés

    Kezelés: Combined metabolic activators

  • Placebo ArmPlacebo, összehasonlításként

    Kezelés: Collagen and maltodextrin

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. október 27.